Kamada Stock Appears To Be Fairly Valued
- By GF Value
The stock of Kamada (NAS:KMDA, 30-year Financials) shows every sign of being fairly valued, according to GuruFocus Value calculation. GuruFocus Value is GuruFocus' estimate of the fair value at which the stock should be traded. It is calculated based on the historical multiples that the stock has traded at, the past business growth and analyst estimates of future business performance. If the price of a stock is significantly above the GF Value Line, it is overvalued and its future return is likely to be poor. On the other hand, if it is significantly below the GF Value Line, its future return will likely be higher. At its current price of $6.17 per share and the market cap of $275.1 million, Kamada stock appears to be fairly valued. GF Value for Kamada is shown in the chart below.
Because Kamada is fairly valued, the long-term return of its stock is likely to be close to the rate of its business growth, which averaged 3.4% over the past five years.
Link: These companies may deliever higher future returns at reduced risk.
Companies with poor financial strength offer investors a high risk of permanent capital loss. To avoid permanent capital loss, an investor must do their research and review a company's financial strength before deciding to purchase shares. Both the cash-to-debt ratio and interest coverage of a company are a great way to to understand its financial strength. Kamada has a cash-to-debt ratio of 22.12, which which ranks better than 82% of the companies in Drug Manufacturers industry. The overall financial strength of Kamada is 8 out of 10, which indicates that the financial strength of Kamada is strong. This is the debt and cash of Kamada over the past years:
It is less risky to invest in profitable companies, especially those with consistent profitability over long term. A company with high profit margins is usually a safer investment than those with low profit margins. Kamada has been profitable 6 over the past 10 years. Over the past twelve months, the company had a revenue of $133.2 million and earnings of $0.39 a share. Its operating margin is 14.44%, which ranks better than 73% of the companies in Drug Manufacturers industry. Overall, the profitability of Kamada is ranked 6 out of 10, which indicates fair profitability. This is the revenue and net income of Kamada over the past years:
Growth is probably the most important factor in the valuation of a company. GuruFocus research has found that growth is closely correlated with the long term performance of a company's stock. The faster a company is growing, the more likely it is to be creating value for shareholders, especially if the growth is profitable. The 3-year average annual revenue growth rate of Kamada is 3.4%, which ranks in the middle range of the companies in Drug Manufacturers industry. The 3-year average EBITDA growth rate is 23.4%, which ranks better than 77% of the companies in Drug Manufacturers industry.
Another way to look at the profitability of a company is to compare its return on invested capital and the weighted cost of capital. Return on invested capital (ROIC) measures how well a company generates cash flow relative to the capital it has invested in its business. The weighted average cost of capital (WACC) is the rate that a company is expected to pay on average to all its security holders to finance its assets. We want to have the return on invested capital higher than the weighted cost of capital. For the past 12 months, Kamada's return on invested capital is 22.46, and its cost of capital is 6.94. The historical ROIC vs WACC comparison of Kamada is shown below:
To conclude, the stock of Kamada (NAS:KMDA, 30-year Financials) appears to be fairly valued. The company's financial condition is strong and its profitability is fair. Its growth ranks better than 77% of the companies in Drug Manufacturers industry. To learn more about Kamada stock, you can check out its 30-year Financials here.
To find out the high quality companies that may deliever above average returns, please check out GuruFocus High Quality Low Capex Screener.
This article first appeared on GuruFocus.
